PODDMEDIUM SIGNALFINANCIAL10-K

PODD delivered strong revenue growth of 31% and operating income surge of 53%, but net income declined 41% due to increased investments in R&D and operations.

The company is experiencing robust top-line growth in its insulin delivery systems while strategically investing heavily in R&D (up 37%) and expanding operations, which temporarily compressed net margins. The substantial increase in operating cash flow (+32%) and stockholders' equity (+25%) indicates the business fundamentals remain strong despite the earnings decline.

Comparing 2026-02-18 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

PODD demonstrated impressive operational momentum with revenue growing 31% to $2.7B and gross profit expanding 34% to $1.9B, driving operating income up 53% to $474M. However, aggressive investments in R&D (+37%) and SG&A (+27%), combined with what appears to be higher tax expenses or one-time charges, caused net income to fall 41% to $247M despite strong operating performance. The healthy 32% growth in operating cash flow to $569M and 25% increase in stockholders' equity to $1.5B suggests the company is successfully reinvesting profits for future growth while maintaining strong cash generation capabilities.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+53.4%
$308.9M→$473.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
+53.4%
$124.9M→$191.6M

Capital expenditure jumped 53.4% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
-40.9%
$418.3M→$247.1M

Net income declined 40.9% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+37.1%
$219.6M→$301.1M

R&D investment increased 37.1% — signals commitment to future product development, though near-term margin impact.

Gross Profit
P&L
+34.2%
$1.4B→$1.9B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Operating Cash Flow
Cash Flow
+32.3%
$430.3M→$569.3M

Operating cash flow surged 32.3% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+30.7%
$2.1B→$2.7B

Strong top-line growth of 30.7% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+28.7%
$528.4M→$680.1M

Current liabilities rose 28.7% — increased short-term obligations, watch current ratio.

SG&A Expense
P&L
+27%
$917.2M→$1.2B

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Stockholders Equity
Balance Sheet
+25.1%
$1.2B→$1.5B

Equity base grew 25.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-18
PRIOR — 2025-02-21
ADDED
Historically, type 2 diabetes has occurred in later adulthood, but its incidence is increasing among children and young adults, due primarily to increasing obesity.
and international insulin-requiring type 2 diabetes population and the U.S.
MDI therapy also requires a separate injection of a long-acting (basal) insulin, to control glucose levels between meals.
The small, lightweight, self-adhesive disposable tubeless Omnipod device ( Pod ), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back.
Omnipod products provide for virtually pain-free automated cannula (a small flexible tube) insertion through which insulin is delivered, eliminating the need for MDI or the use of pump and tubing.
+7 more — sign up free →
REMOVED
Historically, type 2 diabetes has occurred in later adulthood, but its incidence is increasing among the younger population, due primarily to increasing obesity.
and international insulin-intensive type 2 diabetes population and the U.S.
MDI therapy may also require a separate injection of a long-acting (basal) insulin, to control glucose levels between meals; typically, once or twice per day.
The small, lightweight, self-adhesive disposable tubeless Omnipod device ( Pod ), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube (called a cannula).
The embedded algorithm utilizes these glucose values to predict glucose levels into the future and automatically adjusts insulin dosing intended to improve time-in-range and reduce the occurrence of blood glucose highs and lows.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →